NeurogesX is a specialty pharmaceutical company engaged in the development and commercialization of a portfolio of novel non-opioid pain management therapies. The company’s lead product, Qutenza – currently approved in the U.S. and the E.U. – is now available in the United States for the management of pain associated with postherpetic neuralgia. In Europe, Qutenza is being marketed for the treatment of neuropathic pain in non-diabetic adults. For more information visit the company’s Web site at www.neurogesx.com

ROTH Capital Partners is a relationship-driven investment bank that primarily focuses on connecting small-cap publicly traded companies with institutional investors. This year’s annual ROTH conference will take place at The Ritz Carlton located in Dana Point, CA, on March 11-14. Bringing together executives from more than 400 growth companies, the 24th Annual ROTH Conference is one of the largest of its kind in the U.S. For more information on ROTH Capital Partners, visit www.roth.com

Let us hear your thoughts below: